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Non-Invasive MRI and Spectroscopy of mdx Mice Reveal
Temporal Changes in Dystrophic Muscle Imaging and in
Energy Deficits
Christopher R. Heier1, Alfredo D. Guerron1, Alexandru Korotcov2, Stephen Lin2,
Heather Gordish-Dressman1,3, Stanley Fricke4, Raymond W. Sze5, Eric P. Hoffman1,3, Paul Wang2,6,
Kanneboyina Nagaraju1,3*
1 Center for Genetic Medicine Research, Children’s National Medical Center, Washington, D.C., United States of America, 2 Department of Radiology, Howard University
College of Medicine, Washington, D.C., United States of America, 3 Department of Integrative Systems Biology, George Washington University School of Medicine and
Health Sciences, Washington, D.C., United States of America, 4 Department of Diagnostic Imaging and Radiology, Children’s National Medical Center, Washington, D.C.,
United States of America, 5 Department of Radiology, Children’s National Medical Center, Washington, D.C., United States of America, 6 Department of Electrical
Engineering, Fu Jen Catholic University, Taipei, Taiwan

Abstract
In Duchenne muscular dystrophy (DMD), a genetic disruption of dystrophin protein expression results in repeated muscle
injury and chronic inflammation. Magnetic resonance imaging shows promise as a surrogate outcome measure in both
DMD and rehabilitation medicine that is capable of predicting clinical benefit years in advance of functional outcome
measures. The mdx mouse reproduces the dystrophin deficiency that causes DMD and is routinely used for preclinical drug
testing. There is a need to develop sensitive, non-invasive outcome measures in the mdx model that can be readily
translatable to human clinical trials. Here we report the use of magnetic resonance imaging and spectroscopy techniques
for the non-invasive monitoring of muscle damage in mdx mice. Using these techniques, we studied dystrophic mdx muscle
in mice from 6 to 12 weeks of age, examining both the peak disease phase and natural recovery phase of the mdx disease
course. T2 and fat-suppressed imaging revealed significant levels of tissue with elevated signal intensity in mdx hindlimb
muscles at all ages; spectroscopy revealed a significant deficiency of energy metabolites in 6-week-old mdx mice. As the
mdx mice progressed from the peak disease stage to the recovery stage of disease, each of these phenotypes was either
eliminated or reduced, and the cross-sectional area of the mdx muscle was significantly increased when compared to that of
wild-type mice. Histology indicates that hyper-intense MRI foci correspond to areas of dystrophic lesions containing
inflammation as well as regenerating, degenerating and hypertrophied myofibers. Statistical sample size calculations
provide several robust measures with the ability to detect intervention effects using small numbers of animals. These data
establish a framework for further imaging or preclinical studies, and they support the development of MRI as a sensitive,
non-invasive outcome measure for muscular dystrophy.
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translational medicine. Several such compounds have now begun
to enter clinical trials, including drug classes that target either the
skipping of problematic exons [1–3] or inflammation and
membrane stability [4].
Two significant problems encountered thus far in the case of
DMD and related translational areas are a lack of quantitative
surrogate outcome measures [5] and a poor success rate in
translating success in preclinical mouse trials into success in human
clinical trials [6–8]. Currently, many outcome measures used in
early DMD trials consist of measures that can be subjective, could

Introduction
Duchenne muscular dystrophy (DMD) is the most common
lethal genetic muscle disease diagnosed in children. Dystrophindeficient mdx mice are a naturally occurring genetic model of
DMD and are widely used for preclinical drug testing. Both DMD
and mdx muscle undergo cycles of degeneration and regeneration,
resulting in a chronic inflammatory state in skeletal muscle.
Together, a clearly defined genetic cause and animal models
establish a logical path for developing therapies for DMD through
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wild-type (C57BL/10ScSnJ) female mice were obtained from the
Jackson Laboratory (Bar Harbor, ME). Groups for the longitudinal study initially consisted of six wild-type and six mdx mice each.
One wild-type mouse stopped breathing under anesthesia and was
removed from the study. Mice were received at 4 weeks of age,
allowed to acclimate for 2 weeks, and assayed beginning at 6 weeks
of age. MRI and NMR spectroscopy were performed on each
mouse every 2 weeks until the mice were 12 weeks of age. To
immobilize the animals for MRI and NMR spectroscopy scans,
they were anesthetized with 1.5% isoflurane, gently restrained in
imaging position upon a plastic plate, and positioned in the center
of the MRI scanner. For imaging, mice were placed in a holder
that maintained their temperature at 37uC, with monitoring of
their body temperature as well as respiratory and heart rates.
Hindlimb muscles were examined in two sites per animal,
including the leg and the thigh.

be susceptible to coaching effects or placebo effects, or show high
variability [5,9]. In preclinical mdx studies, most outcome
measures used are unique to mice or must be substantially altered
or interpreted to account for species differences.
Magnetic resonance imaging (MRI) is the gold standard for
imaging damage to soft-tissue such as muscle. MRI is a noninvasive technique that does not require anesthesia in humans. It
provides advantages over microCT, X-ray, and ultrasound
imaging techniques in that it does not use ionizing radiation,
and provides high-resolution imaging with strong contrast in soft
tissues [10,11]. Early MRI and nuclear magnetic resonance
(NMR) spectroscopy studies have shown clear differences between
DMD and healthy muscle. Adipose tissue replacement of muscle is
prominent in standard T2-weighted MRI imaging of advancedstage DMD patients [12,13]. Fat-suppression MRI techniques
allow for enhanced imaging of edema and inflammation [12].
Nuclear magnetic resonance spectroscopy techniques show that
DMD muscle is in a state of energy deficiency [14], and detect
increased lipid content within muscle [15]. Given these studies
establishing dystrophic muscle phenotypes, together with studies
comparing clinical groups [16], changes over time [17], and
correlation with clinical assessments [18,19], MRI is emerging as a
potential key surrogate outcome measure for DMD clinical trials.
Here, we use MRI methodologies to study muscle damage and
changes over time in mdx mice. One characteristic of the mdx
disease is the period of peak necrosis and disease severity from 3 to
6 weeks of age; this severe disease is followed by a recovery period
that produces mild phenotypes in the mice by 10–12 weeks of age
[20–23]. We use a longitudinal strategy in which we image the
same mice and muscles repeatedly from 6 to 12 weeks of age. This
approach has several advantages: it examines two distinct disease
phases, longitudinal measures increase statistical power, it
facilitates design of non-invasive studies with technologies that
are translatable to human muscle, and by assaying natural
recovery periods it provides an idea of what therapeutic efficacy
could look like. Here, we show clear MRI and NMR spectroscopy
phenotypes in 6-week mdx mice in comparison to wild-type. These
phenotypes include measures of muscle damage and a deficiency
in energy metabolites. Interestingly, many of these differences are
eliminated or reduced as mdx mice transition into the recovery
phase of disease. Taken together, our results support the noninvasive use of MRI surrogate outcome measures for diagnosis,
prognosis, and rehabilitation of muscle damage in muscular
dystrophy.

MRI and NMR spectroscopy
In vivo monitoring of mouse hindlimbs and muscle damage was
performed using a 9.4 T, 89-mm vertical bore NMR spectrometer
(Bruker Biospin MRI, Billerica, MA) with a 25-mm inner diameter
dual nucleus (31P/1H) birdcage coil. For anatomical positioning, a
pilot image set of three orthogonal imaging planes were used. MRI
pulse sequences used for data acquisition used T2-weighted
imaging (T2) and fat-suppressed T2-weighted imaging (FS)
sequences optimized for imaging of muscle inflammation. The
imaging sequence used was a rapid acquisition with relaxation
enhancement (RARE) sequence: echo time (TE) = 7.4 ms;
repetition time (TR) = 3,000 ms; RARE factor 16; flip angle
a = 90u; field of view = 2.56 cm62.56 cm; slice thickness = 1 mm
with no gap between slices; matrix size = 2566256; number of
averages = 12.
Spectra were processed using TopSpin v1.5 software (Bruker
Biospin MRI, Billerica, MA). For 31P spectroscopy studies, unlocalized single-pulse spectroscopy was performed with 4k
transients and a band width of 50 ppm. Integral areas of spectral
peaks corresponding to inorganic phosphorous (Pi), phosphocreatine (PCr), and the three phosphate groups of adenosine
triphosphate (a-ATP, b-ATP, and c-ATP) were measured. Pi
peaks were not detectable in several of the mice assayed (3 mdx
and 5 wild-type); for these mice Pi values were uniformly omitted
from the analyses. The presence of phosphomonoester (PME) or
phosphodiester (PDE) peaks was also recorded; however, the
signal-to-noise ratio of these peaks was not always adequate for
accurate quantification. Levels of PCr and Pi were normalized by
dividing by either the total ATP present in that spectrum or by the
amount of b-ATP present in that spectrum. The results were
consistent between both of these normalization methods; data are
presented as the ratio of each parameter to total ATP.
For analysis of MRI images, two-dimensional sequential (2dseq)
files were converted to digital imaging and communications in
medicine (DICOM) files and analyzed using ImageJ v1.48 (NIH)
software. To obtain volumetric data and account for possible
variability between individual MRI slices, multiple consecutive
MRI slices of each leg and thigh were assembled into image stacks
encompassing 5- or 3-mm sections of the mouse hindlimb. Each
stack was analyzed individually, and values for the two legs or
thighs of each mouse were then averaged to obtain a single value
for that mouse. For the leg, five consecutive slices along the long
axis of the tibia were assayed, beginning 2 mm distal from the
tibial plateau as a reference point to ensure mice were assayed at
the same anatomical location. For the thigh, three consecutive
slices along the long axis of the femur were assayed, beginning
6 mm proximal from the femoral condyles. Within each slice,

Materials and Methods
Ethics Statement
All animal work was conducted according to relevant national
and international guidelines. All studies were reviewed and
approved by the Institutional Animal Care and Use Committee
of Children’s National Medical Center, the Washington DC
Veterans Affairs Medical Center Institutional Animal Care and
Use Committee, and by the Howard University Institutional
Animal Care and Use Committee.

Animal care
All experiments were conducted according to protocols
approved by the Institutional Animal Care and Use Committees
of Children’s National Medical Center, the Washington DC
Veterans Affairs Medical Center, and Howard University.
Animals were maintained in a controlled mouse facility with a
12 h light: 12 h dark photoperiod, fed ad libitum, and monitored
daily for health. All mdx (C57BL/10ScSn-DMD,mdx./J) and
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regions of interest were digitally traced in ImageJ for each leg such
that they were defined as the total area internal to the leg or thigh.
Within regions of interest in each individual MRI image, we
measured the total cross-sectional area, as well as the volumetric
area (in voxels, or volume pixels) of bone, of muscle (with bone
subtracted), and of tissue exceeding threshold signal intensity. For
cross-sectional area, the highest value for each leg or thigh was
recorded as the maximal cross-sectional area (CSAmax). Bone was
measured by digitally tracing the dark outline shape of the tibia or
femur in MRI images, and measuring the area outlined. Muscle
area was measured by subtracting bone from the combined muscle
and bone area making up the full region of interest. Elevated signal
intensity was measured using ImageJ software in a semi-automated
manner by measuring the volumetric area in voxels that exceeded
background threshold within the regions of interest. Percent of
tissue with elevated signal intensity was calculated by dividing this
measurement by the area in voxels measured for muscle.

Results
NMR spectroscopy shows mdx energetics deficit
To determine the state of energy metabolites in mdx versus
healthy mice, we assayed the relative levels of phosphate
metabolites in mice using un-localized 31P spectroscopy. Here,
the levels of phosphocreatine (PCr), inorganic phosphate (Pi), and
adenosine triphosphate (ATP, with a-, b- and c- peaks
corresponding to its three phosphate groups) were assayed every
2 weeks beginning at 6 weeks of age (Figure 1A). At 6 weeks of age,
PCr levels were significantly lower in mdx than in wild-type mice,
with PCr:ATP ratios of 0.4460.05 and 0.5860.03 (p#0.001),
respectively (Figure 1B). The difference in PCr levels between mdx
and wild-type mice was reduced by 8 weeks of age, as the mdx
mice entered the recovery stage of their disease, with mdx levels
resembling wild-type and no significant difference present from 8
weeks to 12 weeks of age. In contrast to PCr, the levels of Pi:ATP
were significantly increased (p,0.05) in mdx mice compared to
wild-type at both 6 weeks and 8 weeks of age, after which they
resembled wild-type (Figure 1C). These findings indicate that at 6
weeks of age, during the peak stage of mdx weakness and necrosis
[20,22,23], the mdx mice experience an energy metabolism
deficiency that subsequently improves during the recovery phase.

Histology
Mice were assayed by T2 imaging of the leg as described above.
Immediately after each imaging session, the imaged mouse was
sacrificed and the whole leg fixed in formalin. This was performed
with 3 mdx and 2 wild-type mice at 6 months of age. Paraffin
cross-sections of the legs were made at locations of interest
corresponding to MRI slices as specified in a sagittal positioning
image (Histoserv, Inc.), and sections were stained with H&E.
Images were obtained using an Olympus BX61TRF (Olympus,
Center Valley, PA) microscope with an Olympus DP71 camera
and Olympus DP Controller v3.2.1.276 software. Using ImageJ
software, digital tracing and overlap of the tibia structure between
H&E and MRI images was used to confirm anatomical location
within a corresponding MRI slice. T2 images for specific slices
were then compared to corresponding H&E images for qualitative
analysis within regions of interest. Multiple images taken with a 46
objective were used to produce full cross-sectional H&E montage
images of the leg, and an inset image within a representative area
was taken with a 106 objective. Histopathology was assayed
qualitatively as reported previously [24].

Longitudinal MRI of mdx muscle detects effects of mdx
genotype and age
To image dystrophic muscle in live mice during the peak
necrosis and recovery phases of the mdx condition, we performed
T2-weighted imaging and fat-suppressed imaging of leg and thigh
muscles every 2 weeks, from 6 to 12 weeks of age. Heterogeneous
areas of elevated intensity were visible in all mdx mice and at all
time points, in contrast to the more uniform and dark signal for
healthy control muscle tissue (Figure 2A). Orientation and
relevant anatomy are provided (Figure 2B). By aligning anatomically matched MRI slices using the tibial plateau as a reference
point across successive time points, we observed qualitative
changes in the sites and patterns of hyperintense foci within mdx
leg muscles between two-week intervals.
Quantitatively, we detected significant effects of the mdx
genotype on measures of muscle damage and size by both T2weighted and fat-suppressed imaging, in both the leg and thigh
muscles. No significant differences were observed in volumetric
bone area between mdx and wild-type, for either the tibia or
femur, for any of the imaging methods (Figure S1). In T2 imaging
of mdx leg muscles, we found a significant increase in the
percentage of tissue with elevated intensity (p,0.001) that changed
over time (p,0.01), without a significant interaction effect being
present. In T2 images of leg muscle, 6-week-old mdx mice had
2163% tissue with elevated signal, as compared to 462% for
wild-type mice (p,0.001; Figure 2C). As the mdx mice entered the
recovery phase of disease, they showed a 38% reduction in the
levels of affected tissue, to a mean of 1362% of volume pixels
(voxels) with elevated intensity at 8 weeks of age (p,0.001). These
values then remained fairly steady, with no significant decrease
from 8 to 12 weeks of age. These data illustrate the ability of MRI
to detect significant levels of affected tissue in dystrophic legs in 6to 12-week old mdx mice.
We also wanted to gain insight into whether affected muscle in
mdx is either being eliminated or being ‘‘diluted’’ as the muscle
grows larger and enters the recovery phase. To do this, we assayed
the absolute volume of tissue with elevated intensity in the legs as
well as the cross-sectional area of the legs. We detected a
significant effect of the mdx genotype (p,0.001), with increased
volume of elevated signal over wild-type at all ages (Figure 2D).

Statistical Analysis
All statistical analyses were performed by a dedicated biostatistician. Separate regression models were run for each measurement, method, and site. All models were mixed effects linear
regression models with the mouse ID as the random coefficient.
This approach allowed us to take into account the repeated
measures taken at each time point. The main effects of strain and
time were tested. All within-strain measurements were approximately normally distributed; therefore, no normalizing transformations were used. All single time-point strain comparisons were
done using t-tests without adjustment for multiple testing to
facilitate the powered design of trials with single time points.
Sample size calculations were performed to determine the number
of mice needed to detect a significant change with treatment, to
facilitate future preclinical and proof-of-concept studies. Calculations were performed on mdx mice only, with the expectation that
WT mice would not show the level of changes in inflammation
and muscle changes expected in mdx mice. For PCr, the percent of
voxels with elevated signal, maximum CSA, and volume of tissue
with elevated intensity, we performed calculations to show a 20%
change in mean value. Power analyses were one-sided in the
direction of mdx value movement toward wild-type values and
assumed a power of 80% and an alpha = 0.05. Throughout the
text, all data are presented as means 6 standard deviation unless
otherwise noted.
PLOS ONE | www.plosone.org
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Figure 1. 31P NMR spectroscopy indicates an energy deficit in 6-week-old mdx mice. Beginning at 6 weeks of age, mdx and wild-type (WT)
mice were assayed by 31P spectroscopy every 2 weeks. A) Representative 31P NMR spectra illustrating the peaks of several energy metabolites in one
wild-type (left) and one mdx (right) mouse, from weeks 6 through 12. The inorganic phosphate, phosphocreatine, and three phosphate group peaks
for ATP are labeled and marked by a tick mark. Graphs are aligned by parallel lines connecting the ATP peaks; phosphocreatine and inorganic
phosphate showed differences between wild-type and mdx mice and are highlighted by a red box. B) Phosphocreatine levels are decreased in 6week-old mdx mice, then change to near wild-type levels during the mdx recovery phase. C) Inorganic phosphate levels are elevated at 6 and 8 weeks
in mdx mice compared to wild-type, then change to near wild-type levels by 10 weeks. Note, peaks for inorganic phosphate were not detectable in
several mice of both genotypes (3 mdx and 5 wild-type); values for these mice were uniformly omitted from the Pi analysis (Pi, inorganic phosphate;
PCr, phosphocreatine; ATP, adenosine triphosphate; tATP, total ATP; n = 3–6 mice per data point; data are means 6SEM; *p#0.05, ***p#0.001).
doi:10.1371/journal.pone.0112477.g001

We detected no significant effects of time on the volume of
elevated signal in mdx mice and no significant interaction effect.
Examining the sizes of muscles throughout the 6- to 12-week
period assayed, we detected significant effects of the mdx genotype
(p,0.001) and of time (p,0.001) on CSAmax, without a significant
interaction effect. Initially, the mdx mice showed a smaller but
significant increase over wild-type in CSAmax (p,0.05), with
values of 27.761.3 mm2 versus 24.762.6 mm2, respectively
(Figure 2E). In contrast to the results for elevated signal, as the
mdx mice progressed into the recovery phase, differences in
CSAmax between the mdx and wild-type mice became larger, with
the difference increasing by 113% from week 6 to week 8. At 8
weeks, mdx calves had CSAmax values of 34.762.2 mm2, versus
28.462.5 mm2 for wild-type (p,0.01), and this difference was
maintained through 12 weeks of age, at which point the mdx mice
had CSAmax values of 40.063.9 mm2, versus 33.561.3 mm2 for
wild-type (p,0.01). Together, these MRI data show that as mdx
mice recover from the necrotic phase and assume a milder
phenotype [20,22,23], they show a decrease in the percentage of
affected tissue driven by an increase in muscle size, without a
complete resolution of phenotype.
PLOS ONE | www.plosone.org

To enhance the visualization of signal from possible edema and
inflammation, given the reduced signal likely from possible fatty
infiltration of the muscle, we performed fat-suppressed imaging
immediately following the standard T2-weighted imaging (Figure 3). Here again, we saw significant phenotypes in 6-week old
mdx mice, with an average of 963% tissue with elevated intensity
present in mdx mice, versus 161% for wild-type mice (p,0.001).
Following week 6, mdx mice again showed a 40% reduction in
affected leg tissue as they entered the recovery phase of disease, to
564% versus 0.660.3% for wild-type (p,0.05) at 8 weeks. Values
for both genotypes were then maintained at similar levels through
12 weeks of age. These data are consistent with the T2 imaging
results.
For the thigh muscles, results were qualitatively consistent with
those found for the leg muscles; we again observed changes in the
patterns of affected tissue over time within the same mouse in
anatomically aligned MRI slices (Figure 4A). Orientation and
relevant anatomy are provided (Figure 4B). In standard T2
images, 6-week old mdx mice showed a significant increase in
the percentage of tissue with elevated signal, with values of
2265% versus 761% for wild-type mice (p,0.001; Figure 4C).
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Figure 2. T2 of mdx leg shows changes in dystrophic muscle and cross-sectional area over time. A) Representative T2-weighted images
from one mdx mouse (left) and one wild-type mouse (right) over time, each imaged from 6 to 12 weeks of age. The full MRI image of each mouse is
provided on the outside column, with the leg of the left hindlimb for each mouse outlined in white and a magnified version of the leg muscles
provided in the center columns. The black arrows mark a region of mdx muscle that showed a reduction in intensity between time points, while the
gray arrows mark a region that showed an elevation of intensity between time points. The tibia, visible as a triangular structure in the upper right
corner of each leg section, was used to orient the muscle slices. B) Orientation and anatomy of the leg cross sections. Anterior muscle groups (A,
yellow) include tibialis anterior and extensor digitorum longus. Medial muscle groups (M, orange) include flexor hallucis and flexor digitorum.
Posterior muscle groups (P, red) include gastrocnemius, soleus, and plantaris. The tibia bone is also marked (T). C) The percentage of tissue within the
leg muscle that showed signal intensity elevated over the threshold that separates healthy muscle from affected tissue illustrates a change between
the necrotic (6 week) and recovery phases of mdx disease. D) The absolute volume of tissue with elevated signal intensity detected within the leg of
mice. E) The CSAmax values over time show the growth of muscle, and an increase for the mdx mice as compared to wild-type mice (n = 5 wild-type
and 6 mdx mice; data are means 6SEM; *p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0112477.g002
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Figure 3. Longitudinal fat-suppressed imaging of dystrophic mdx leg muscles. A) Representative fat-suppressed images of leg muscle from
the left hindlimb of one mdx (top) and one wild-type (bottom) mouse over time, each imaged from 6 to 12 weeks of age. Black arrows mark a region
of muscle that showed a reduction in intensity between time points, while gray arrows mark a region that showed an increased intensity between
time points. The tibia is present as a triangular structure in the upper right corner of the leg sections. B) The percentage of tissue within the leg that
has an elevated signal intensity shows a difference between mdx and wild-type mice at all time points and illustrates a change between the peak
disease (6 week) and recovery phases of mdx disease (n = 5 wild-type and 6 mdx mice; data are means 6SEM; *p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0112477.g003

This parameter decreased steadily over time for the mdx thigh, to
1465% for mdx and 561% for wild-type mice at 12 weeks
(p,0.01). Examining the absolute volume of tissue with increased
signal independent of muscle size, we found a significant effect of
the mdx genotype at all time points (p,0.01), but no significant
effect of time over the ages assayed (Figure 4D). The size of the
thigh muscle, as measured by CSAmax, was not significantly
different between genotypes at 6 weeks of age (Figure 4E).
However, as with the leg, CSAmax increased for the mdx thighs
when compared to wild-type, beginning at 8 weeks of age with
values of 57.962.4 mm2 for mdx versus 49.366.4 mm2 for wildtype (p,0.05). This size differential continued to increase through
12 weeks, to 73.067.5 mm2 for mdx versus 57.063.2 mm2 for
wild-type mice (p,0.01).
In fat-suppressed imaging of the thigh, mdx mice again showed
a significant increase in the percentage of tissue with elevated
signal at 6 weeks, with 1766% as compared to 261% for wildtype (p,0.001; Figure 5). By 10 weeks of age, this decreased to
961% for mdx and 261% for wild-type (p,0.001) as the mice
progressed to the recovery stage of disease. Together, thigh data
are in agreement with the leg. These data illustrate that mdx mice
show a substantial decrease in the percentage of affected tissue and
an increase in muscle area as they progress from the peak disease
phases [20,22,23] to the recovery phase of the disease.

wild-type controls. Results were consistent between individual
mice with the same genotype. These data indicate areas of
elevated intensity in dystrophic mdx muscle correspond to
dystrophic lesions that include a combination of inflammation
with degenerating and regenerating myofibers.

Statistical power calculations suggest assays to use for
lowest sample size
To determine the methodology that may be of best utility in
preclinical drug or intervention efficacy studies, we performed
statistical sample size calculations on MRI and spectroscopy data.
Here, we calculated the sample sizes of mdx mice needed to detect
20% changes in mdx metabolite or imaging measures; in previous
studies, we detect up to 40% to 50% effects from drug treatment
on measures of muscle pathology and inflammation in similar aged
mdx mice [4]. Our statistical power analyses indicated that 31P
NMR spectroscopy performed along with T2 imaging of leg
muscles at 6 weeks of age requires the lowest number of mdx mice
to detect drug efficacy. At 6 weeks of age significant phenotypes
are presented, and 20% intervention effects can be detected with 4
mdx mice for 31P phosphocreatine levels, and with 7 or 8 mice for
T2 quantification of affected tissue in leg muscle (Table 1). In
contrast to the leg, T2 measurements in 6-week-old mdx thighs
required 13 or more mice for detection of drug effects. Using fat
suppression acquisition methods increased the number of 6-week
old mice needed for detection of intervention effects to 39 or more
mice for both muscle groups. As mdx mice grew older, the number
of mice needed to detect intervention effects in T2 images also
increased to 22 or more at week 12, while 31P phenotypes were
absent (Table S1). Together, these data indicate that a protocol of
leg T2 MRI combined with 31P spectroscopy in mice that are 6
weeks of age provides several sensitive outcome measures for mdx
studies.

Histopathology present in affected areas of dystrophic
mdx leg MRI
To determine pathology present within areas of elevated
intensity in MRI of mdx hindlimb muscles, we performed an
additional experiment comparing H&E histology to matched MRI
slices (Figure 6). Here, T2 images of the leg were obtained in 6month old mdx and wild-type mice, with legs collected for
histology immediately following MRI. Consistent with younger
mice, mdx mice but not wild-type mice displayed heterogeneous
patterns with foci of elevated signal intensity in their leg muscles
(Figure 6A–B). By comparing matched H&E stained sections to
MRI slices, we found areas of increased MRI intensity in
dystrophic muscle correspond to histology regions containing a
mix of inflammation, degenerating fibers, regenerating fibers, and
hypertrophic fibers (Figure 6C–D). Inflammation and myofiber
degeneration or regeneration were not observed in either of the
PLOS ONE | www.plosone.org

Discussion
MRI shows promise as a surrogate outcome measure for DMD
that is capable of non-invasively detecting muscle damage in
patients. Here we use magnetic resonance technologies to identify
and longitudinally characterize phenotypes in the mdx model of
DMD. Since mdx mice naturally show a peak of necrosis, weakness
6
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Figure 4. Changes in T2 imaging and cross-sectional area of dystrophic mdx thighs over time. A) Representative T2-weighted images of
thigh muscle from the right hindlimb of one mdx and one wild-type mouse over the study period. The black arrows mark a region of muscle that
showed a reduction in intensity over time, while the gray arrows mark a region that showed an increased intensity over time. The femur is visible as
an elliptical structure towards the center of the thigh. B) Orientation and anatomy of thigh cross sections. Anterior muscle groups (A, yellow) include
vastus intermedius, vastus lateralis, and rectus femoris. Lateral muscle groups (L, orange) include biceps, semitendinosus and semimembranosus
muscles. Medial muscle groups (M, red) include gracilis and adductor muscles. The femur bone (F) is also marked. C) The percentage of tissue within
the thigh muscle that showed a signal intensity elevated over the threshold that separates healthy muscle from affected tissue shows a difference
between mdx and wild-type mice at all time points. D) The absolute volume of tissue with an elevated signal within the thigh of mdx and wild-type
mice. E) CSAmax shows growth of the muscle size over time, and an increase in the cross-sectional area of the thigh muscle in mdx mice as compared
to wild-type mice from 8 weeks onward (n = 5 wild-type and 6 mdx mice; data are means 6SEM; *p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0112477.g004

Energy metabolites detected using 31P spectroscopy show a
significant deficit of phosphocreatine in 6- to 8-week old mdx mice.
Significant deficits in phosphocreatine and increased inorganic
phosphate are also found in DMD patients [14]. Since energy for
muscle contractions comes from phosphocreatine, which is used
for generation of ATP through a reversible reaction with creatine
phosphokinase, the PCr:ATP ratio is reflective of the energy state
of muscle [26–28]. Thus, the decrease in PCr:ATP reflects a
muscle bioenergetics deficit in both dystrophic 3- to 12-year-old
DMD patients [14] and 6-week-old mdx mice. Similar results have

and disease at 3 to 6 weeks of age [20–23], followed by a natural
recovery phase in which they show only mild skeletal muscle
disease, the peak disease phase is commonly used to assess
preclinical efficacy of therapeutics [4,25]. We find mdx mice show
significant imaging and spectroscopic alterations during this peak
disease phase. Furthermore, these changes decrease as mice
progress to the recovery phase. Our findings indicate non-invasive
MRI and NMR spectroscopy are sensitive outcome measures that
can be used to study disease and evaluate potential therapies in the
mdx model of muscular dystrophy.
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Figure 5. Longitudinal fat-suppressed MRI of dystrophic mdx thigh muscles. A) Representative fat-suppressed images of thigh muscle from
the right hindlimb of one mdx and one wild-type mouse over the course of the study. Black arrows mark a region of muscle that showed a reduction
in intensity over time, while gray arrows mark a region that showed an increase in intensity over time. The femur is visible as an elliptical structure in
the central area of the thigh. B) The percentage of tissue with an elevated signal intensity within the thigh shows a difference between mdx and wildtype mice at all time points (n = 5 wild-type and 6 mdx mice; data are means 6SEM; ***p,0.001).
doi:10.1371/journal.pone.0112477.g005

Figure 6. T2 imaging and histology of the mdx leg. Additional mice were assayed by T2 imaging at 6 months of age, followed by immediate
collection of the whole leg for histology. A) Representative T2 images are provided of mdx (top two rows) and wild-type (bottom row) mice. The
region of interest outlined in white is shown enlarged in (B). C) H&E stained cross section images corresponding to MRI slices in panels A and B. A
montage image of the full leg is provided, with the inset area displayed in (D) at higher magnification (Rectangles in B and C represent the
approximate areas presented in higher magnification images in D; Scale bars = 2 mm in C and 0.5 mm in D).
doi:10.1371/journal.pone.0112477.g006
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Table 1. Statistical sample size calculations to detect intervention effects in mdx mice.

Values at 6 weeks of age
Method

Measure

31

PCr: tATP

T2

% elevated signal
Vol. elevated (mm3)
% elevated signal

P NMR Spec

Fat Suppression

WT mean ±SD

mdx mean ±SD

N per group to detect a 20% change in
mdx

0.58560.030

0.43860.047

4

Leg

462

2163

8

Leg

4.1661.36

22.9163.31

7

Thigh

761

2265

13

Site

Vol. elevated (mm3)

Thigh

7.5260.75

30.8967.33

18

% elevated signal

Leg

161

963

41

Vol. elevated (mm3)

Leg

0.7060.49

10.0063.55

39

% elevated signal

Thigh

161

1766

39

Vol. elevated (mm3)

Thigh

1.6960.73

23.3469.04

58

Abbreviations: NMR Spec, Nuclear Magnetic Resonance spectroscopy; PCr, phosphocreatine; tATP, total adenosine triphosphate; Vol., Volume; WT, wild-type.

been found in ex vivo cardiac studies of mdx mice, where a
decrease in PCr is found in association with a decrease in
mitochondrial content of heart tissue [29]. Consistent with heart
muscle, we and others find significant mitochondrial deficits in
mdx skeletal muscle [30]. Other muscle disorders such as
mitochondrial myopathies and polio paralysis show a deficit in
phosphocreatine levels as well [31,32]. Interestingly, we find the
PCr:ATP ratio in mdx increases to a level not significantly different
from wild-type by 8 to 10 weeks of age. This illustrates an
improvement in energetics of dystrophic mdx skeletal muscle
during the period associated with recovery.
MRI of mdx muscle provides significant phenotypes at all ages
examined, characterized by hyper-intense foci and a more
heterogeneous appearance. Histology shows these imaging phenotypes correspond to dystrophic lesions containing a mix of
inflammation with degenerating, regenerating, and hypertrophic
myofibers. This is consistent with Walter et al, who find
hyperintense regions are consistent with dystrophic lesions and
damaged myofibers enhanced by contrast agents, and who use 1H
spectroscopy in mdx to show minimal fatty infiltration in
comparison to DMD [33]. We see foci of hyper-intense signal
change over time, consistent with a dynamic disease process [20]
and with time frames established for muscle repair following crush
injury [34]. We find cross-sectional area of mdx muscle increases
over time, while absolute volume of dystrophic lesions in imaging
does not. Data in the literature indicate such increases in CSAmax
are the result of hypertrophy and regeneration [23,35–37].
Comparing spectroscopy and imaging results, there is a
discrepancy in mdx mice. Spectroscopy shows an initial energetics
deficit that is eliminated by 8–10 weeks, while imaging phenotypes
improve but persist at all ages examined (including 6 months).
Established muscle histology and function data may provide
insight into these differences. Through matched histology, we find
mdx imaging phenotypes are consistent with sites containing
inflammation along with myofiber degeneration and regeneration.
Previous studies establish this histopathology peaks at 3–6 weeks,
then improves but persists throughout the mdx lifespan [20–23]. In
a longitudinal study we are unable to assay isolated muscles for
function, but isometric force data in the literature establish muscle
function at stages we examined. Throughout the lifespan of their
disease, mdx muscles show deficits in normalized strength, where
force is measured relative to mass (kN/kg) or cross-sectional area
(kN/m2) [4,23,25,37,38]. However, raw absolute force measurePLOS ONE | www.plosone.org

ments (expressed in kN or mN) behave differently. During peak
mdx disease (within ages 3–7 weeks), mdx muscles show deficits in
absolute tetanic forces for extensor digitorum longus (EDL) [23],
soleus [23], tibialis anterior (TA) [21], and diaphragm [39]. As
mdx enter a recovery phase (approximately 2–8 months of age)
strength deficits improve [20] and raw measures of isolated EDL
[23,37], soleus [37], and TA [38] muscle forces are usually at or
above wild-type levels. Comparing these observations and stages, it
may be possible that energetics deficits play a role in decreased raw
isometric forces during peak mdx disease. Consistent with this,
creatine treatment targeting energetics deficits in DMD is found to
both increase phosphocreatine and preserve muscle function over
placebo in a short term study [14]. Alternatively, there may be a
threshold of inflammation and muscle damage that manifests as
metabolite or force deficits, and mice may cross this during
recovery. More investigations will be needed to clarify the
relationship of energetics, histopathology, and strength in mdx
muscle.
Though some measures are consistent between mdx and DMD,
their disease courses have clear differences. A main difference is
that DMD is progressive. As children age they show increasing
weakness, fibrosis, and infiltration of muscle with fatty tissue. MRI
and NMR studies of DMD (summarized in Table 2) show striking
differences from controls as fatty adipose tissue replaces muscle
[13,15,40,41]. In DMD, edema is observed within damaged
muscle [12]. At advanced ages, mdx disease does eventually
progress, with injury phenotypes becoming more pronounced after
8 months [38], cardiac deficits around 9 months [42,43], and
advanced histopathology with susceptibility to rhabdomyosarcoma
around 2 years [44]. However, mdx typically do not progress to a
point with the degree of muscle wasting and fatty infiltration
apparent in DMD. The mdx stages we examine here may be most
consistent with early DMD, where muscle shows weakness,
pathology and inflammation, but patients do not yet exhibit
extensive replacement of muscle with fibrotic and fatty tissue.
Moving forward, many gene therapy, antisense oligos, and nextgeneration drug strategies will indeed want to target early DMD
stages to prevent muscle loss and to target stages with more
myofibers present.
Our power analyses and time course show the period of peak
mdx disease provides a useful window with more severe
phenotypes, 31P energetics phenotypes, and increased statistical
power for detecting intervention effects. Here we calculate sample
9
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Table 2. MR imaging and spectroscopy phenotypes in dystrophinopathies.

Study Description

Assay

Study population

Findings in dystrophy

Our findings in mdx

Banerjee [57]

DMD vs. controls;
effects of creatine

31

DMD; 27 patients,
8 controls

PCr is lower & Pi is
higher in DMD

PCr is lower and Pi higher in
6 week mdx

Forbes [58]

Ambulant DMD
vs. controls

T2 MR Imaging

DMD; 30 patients,
10 controls

CSAmax higher in
DMD (MG, Sol, ST)

CSAmax up for mdx in all
weeks (leg & thigh)

Kinali [13]

Leg muscle of DMD

T2 MR Imaging

DMD; 34 patients

Non-muscle content
and fat higher in DMD

Non-muscle higher in mdx
muscle in all weeks

Newman [15]

Forearms of DMD vs.
controls

1

DMD; 6 patients
aged 9–15 years

Fat content higher in
DMD

No fatty infiltration visible in
mdx

Kim [12]

T1 and FS imaging of
DMD pelvic muscles

Fat-Suppressed T2
Imaging

DMD; 42 patients

DMD Edema; GMa, VL,
GMe most frequent

Inflammation and muscle
damage present in mdx

Dunn [53]

Quantitative MRI of
mdx vs. WT

T2 Mapping

mdx; 32–48 weeks

T2 decrease, 1H
density & water increase

Inflammation and muscle
damage present in mdx

Zhang [29]

Cardiac function and
metabolism in mdx

MRI & ex vivo
Spec

mdx and WT; 32
weeks

Decreased PCr in
heart; RV & LV defects

Decreased PCr in skeletal
muscle

McIntosh [34]

Crush injury and
mdx vs. controls

T2 images

mdx; 8–10 weeks

Dystrophic foci seen;
muscle changes over
21 days post-injury

Changes in natural mdx
lesions between 2 to 4 week
intervals

Stuckey [45]

Cardiac morphology
and function in
mdx vs. controls

Longitudinal
cardiac & Gd MRI

mdx; 4–52 weeks

RV Dysfunction by 1 & LV
by 12 months; fibrosis by
6 months

Heart fibrosis after 6
months; 8 weeks if dosed
with prednisone[4]

Pratt [55]

Case study of a
single mdx leg

MRI

One single mdx
mouse; 5–80 weeks

Peak in MRI hetero-geneity,
recovery after 13 weeks

Peak phenotypes in necrotic
phase, damage persists at
8–12 weeks

Straub [46]

Agent-enhanced MRI of
mdx and Sgca2/2 mice

MS-325 agent MRI

mdx & Sgca2/2;
8–10 weeks

Enhances dystrophic
muscle contrast

Amthor [47]

Albumin targeting of
dystrophic muscle

Gd enhanced MRI

mdx; 11–13 weeks

HSA targets to
dystrophic muscle

Odintsov [48]

MRI detection of
transplanted stem cells

MRI of labeled
stem cells

mdx and dKO;
5–30 weeks

MRI tracks Fe-labeled
stem cells short-term

Martins-Bach [51]

Metabolic profiling
of mdx muscle

In vitro 1H
NMR Spec

Lysates of mdx
muscle; 12–24 weeks

Identified metabolites
altered in mdx lysates

Xu [52]

Metabolic changes in
muscle after injury

1

Injured WT & mdx
TAs; 8 weeks

Intramuscular lipids
increase post injury

Energetics deficit in necrotic
phase

Mathur [54]

Effects of exercise on
T2 values in muscle

T2 Mapping

mdx and WT; 20–60
weeks

T2, affected area up
in mdx & after running

Affected area increased in
necrotic phase

Walter [33]

Gene therapy effects
on dystrophic muscle

T2 Mapping

mdx & csg2/2mice;
1 year post-therapy

MRI tracks gene therapy
efficacy in mdx

6 week mdx leg provides
best stat power

Reference

P NMR Spectroscopy

H NMR Spectroscopy

31

P NMR

H NMR Spec

Abbreviations: CSAmax, maximum cross-sectional area; FS, fat suppressed T2; Gd, gadolinium; GMa, gluteus maximus; GMed, gluteus medius; HSA, human serum
albumin; MR, Magnetic Resonance; MG, medial gastrocnemius; PCr, phosphocreatine; RV, right ventricular; Sg, Sarcoglycan; Sgca, Sarcoglycan alpha; Sol, soleus; ST,
semitendinosus; tATP, total adenosine triphosphate; VL, vastus lateralis; WT, wild-type.
doi:10.1371/journal.pone.0112477.t002

transplanted stem cells [48–50]. Metabolic profiling shows
alterations in injured muscle and lysates of 3- to 6-month old
mdx mice [51,52]. T2 mapping has been performed in 20- to 60week-old mdx [53,54]. One case study reports a single mdx leg
assayed longitudinally to 80 weeks [55]. Dunn et al. initially
showed dystrophic lesions can be detected via MRI and that crush
injuries are repaired over approximately 3 weeks [53], consistent
with our findings for naturally occurring mdx dystrophic lesions.
Mathur and Vohra et al. characterized effects of exercise on mdx,
finding effects of the mdx genotype and of running on muscle T2
and % affected area, with medial muscles particularly affected by
running [54]. Gene correction in mdx and limb girdle muscular
dystrophy mouse models show MRI can be used to detect
therapeutic improvement in muscular dystrophy [33,56].
The mdx mouse provides researchers with a genetic model of
the cause of DMD (dystrophin deficiency), and MRI is emerging
as an important surrogate outcome measure for muscle damage.

sizes needed to detect 20% intervention effects. In our experience
with prednisone and with VBP15, we observe substantially larger
than 20% intervention effects at these ages in mdx mice [4]. For
example, fluorescent live-imaging shows a 52% decrease in
markers of necrosis, and histology a 38% decrease in inflammatory
foci with drug treatment [4]. Over the course of only a few weeks,
we see elimination of 31P spectroscopy phenotypes and a dramatic
reduction in the percentage of muscle affected. These findings will
be valuable for design of imaging and pre-clinical therapeutic
studies, by providing more phenotypes and larger differences from
baseline health in controls.
Other imaging studies provide insight into mdx physiology
(summarized in Table 2), but most avoid the critical necrotic
phase of the mdx disease course. Cardiac MRI shows mdx mice
can exhibit heart dysfunction by one month [45], and decreased
cardiac phosphocreatine content at 8 months [29]. Agents can
help visualize disrupted muscle integrity [46,47] or detect
PLOS ONE | www.plosone.org
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In the present study we have found NMR phenotypes and provide
new information on the dynamic disease process in mdx mice.
Although mdx is typically regarded as a very mild disease model,
we find 31P spectroscopy and T2 imaging of the 6-week old mdx
leg show significant differences from WT mice and could provide
robust outcome measures, even with relatively few animals. These
findings can improve preclinical trial design by reducing the
number of animals required to detect effects, allowing for
longitudinal non-invasive quantification of muscle disease, and
using measures that are translatable to human clinical studies.

volume in assayed T2 sections of the thigh. D) Femur volume as
measured within assayed fat suppressed images of the thigh.
(TIF)
Table S1 Statistical sample sizes to detect 20% intervention effects in mdx mice.
(DOC)
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